

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

06th June, 2024

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
--	--

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”).

Dear Sir(s)/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that the Company has agreed to invest an amount of Rs. 30,00,05,156/- (Rupees Thirty Crores Five Thousand One Hundred and Fifty Six only) in the (Pre-Series A) Compulsorily Convertible Preference Shares of M/s HaystackAnalytics Private Limited.

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith as Annexure I. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Annexure I

Particulars	Remarks
Name of the target entity, details in brief such as size, turnover etc.:	<p>(i) Name of the Target entity: M/s HaystackAnalytics Private Limited (“Haystack”)</p> <p>(ii) Details of Target entity: The Target entity is a company incorporated under the Companies Act, 2013, with CIN: U72900MH2018PTC313413, and having its registered office at CM 03, Society for Innovation & Entrepreneurship (SINE), 4th Floor, KReSIT Building, IIT Bombay, Powai, Mumbai – 400076.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “Arms-length”	The acquisition does not fall under related party transaction.
Industry to which the entity being acquired belongs	Healthcare
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed investment is a strategic investment by the Company. It will help the Company to participate in growing diagnostic space and leveraging Haystack’s expertise in advanced genomic data analysis to drive its business based on the detailed analytics from the generated reports.
Brief details of any governmental or regulatory approvals required for the acquisition	None
Indicative time period for completion of the acquisition	On or before 31 st July, 2024 or such extended period as may be agreed upon.
Nature of consideration- whether cash consideration or share swap and details of the same	Cash consideration
Cost of acquisition or the price at which the shares are acquired;	Rs. 30,00,05,156/- (Rupees Thirty Crores Five Thousand One Hundred and Fifty Six only)
Percentage of shareholding / control acquired and/or number of shares acquired;	16,654 (7.42%) (Pre-Series A) Compulsorily Convertible Preference Shares



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

The Target entity has been incorporated on 04th September, 2018.

The Founders are the Promoters of Haystack, which carries on the business of developing genomic analysis software that enables clinical decision-making through affordable, culture-free, comprehensive, & fast clinical genomics by automating bioinformatic analysis to produce clear and clinically relevant reports and utilization of the genomic data and their analysis for creation of new products for healthcare (“Business”).

Turnover as on: (Rs. in Cr)

31st March, 2023: 3.13

31st March, 2022: 2.01

31st March, 2021: 0.01